Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis

Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable... ObjectiveThe aim of this study was to evaluate the efficacy and safety of antithrombotic regimens and their combinations in preventing thrombotic incidents in patients with stable atherosclerotic cardiovascular disease (S-ASCVD).MethodsA systematic literature search was conducted in the PubMed, Embase, Cochrane Library, Scopus, and Google Scholar databases. The primary comprehensive endpoint was a major adverse cardiovascular event (MACE) composite of cardiovascular death, stroke, or myocardial infarction, while the secondary endpoints were cardiovascular death, all-cause stroke, ischemic stroke, myocardial infarction, and all-cause death. The safety endpoint was major bleeding. Bayesian network meta-regression analysis in R software was used to calculate the final effect size and to correct for the effect of follow-up time on the outcome effect size.ResultsTwelve studies reporting 122,190 patients with eight antithrombotic regimens were included in this systematic review. For the primary composite endpoint, low-dose aspirin plus clopidogrel 75 mg (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.33–0.87) and low-dose aspirin plus rivaroxaban 2.5 mg twice daily (HR 0.53, 95% CI 0.34–0.82) showed significantly better efficacy than clopidogrel monotherapy, and the efficacy was comparable among the first two regimens. Unfortunately, none of the active regimens significantly decreased all-cause death, cardiovascular death branch, and all-cause stroke as part of the secondary endpoints. Low-dose aspirin plus ticagrelor 90 mg twice daily (HR 0.81, 95% CI 0.69–0.94) and low-dose aspirin plus ticagrelor 60 mg twice daily (HR 0.84, 95% CI 0.74–0.95) had a significant advantage in myocardial infarction compared with low-dose aspirin monotherapy, while low-dose aspirin plus 2.5 mg rivaroxaban twice daily (HR 0.62, 95% CI 0.41–0.94) was better than low-dose aspirin in the treatment of ischemic stroke. In the major bleeding branch, low-dose aspirin plus ticagrelor 90 mg twice daily (HR 2.2, 95% CI 1.70–2.90), low-dose aspirin plus ticagrelor 60 mg twice daily (HR 2.1, 95% CI 1.70–2.60), low-dose aspirin plus rivaroxaban 2.5 mg twice daily (HR 1.7, 95% CI 1.30–2.00), and rivaroxaban 5 mg twice daily (HR 1.5, 95% CI 1.20–1.90) showed higher major bleeding risk compared with low-dose aspirin.ConclusionsConsidering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2.5 mg twice daily should be considered the preferred regimen for S-ASCVD patients with low bleeding risk. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/prophylactic-efficacy-and-safety-of-antithrombotic-regimens-in-Oq780Z7g3V
Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-023-00574-9
Publisher site
See Article on Publisher Site

Abstract

ObjectiveThe aim of this study was to evaluate the efficacy and safety of antithrombotic regimens and their combinations in preventing thrombotic incidents in patients with stable atherosclerotic cardiovascular disease (S-ASCVD).MethodsA systematic literature search was conducted in the PubMed, Embase, Cochrane Library, Scopus, and Google Scholar databases. The primary comprehensive endpoint was a major adverse cardiovascular event (MACE) composite of cardiovascular death, stroke, or myocardial infarction, while the secondary endpoints were cardiovascular death, all-cause stroke, ischemic stroke, myocardial infarction, and all-cause death. The safety endpoint was major bleeding. Bayesian network meta-regression analysis in R software was used to calculate the final effect size and to correct for the effect of follow-up time on the outcome effect size.ResultsTwelve studies reporting 122,190 patients with eight antithrombotic regimens were included in this systematic review. For the primary composite endpoint, low-dose aspirin plus clopidogrel 75 mg (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.33–0.87) and low-dose aspirin plus rivaroxaban 2.5 mg twice daily (HR 0.53, 95% CI 0.34–0.82) showed significantly better efficacy than clopidogrel monotherapy, and the efficacy was comparable among the first two regimens. Unfortunately, none of the active regimens significantly decreased all-cause death, cardiovascular death branch, and all-cause stroke as part of the secondary endpoints. Low-dose aspirin plus ticagrelor 90 mg twice daily (HR 0.81, 95% CI 0.69–0.94) and low-dose aspirin plus ticagrelor 60 mg twice daily (HR 0.84, 95% CI 0.74–0.95) had a significant advantage in myocardial infarction compared with low-dose aspirin monotherapy, while low-dose aspirin plus 2.5 mg rivaroxaban twice daily (HR 0.62, 95% CI 0.41–0.94) was better than low-dose aspirin in the treatment of ischemic stroke. In the major bleeding branch, low-dose aspirin plus ticagrelor 90 mg twice daily (HR 2.2, 95% CI 1.70–2.90), low-dose aspirin plus ticagrelor 60 mg twice daily (HR 2.1, 95% CI 1.70–2.60), low-dose aspirin plus rivaroxaban 2.5 mg twice daily (HR 1.7, 95% CI 1.30–2.00), and rivaroxaban 5 mg twice daily (HR 1.5, 95% CI 1.20–1.90) showed higher major bleeding risk compared with low-dose aspirin.ConclusionsConsidering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2.5 mg twice daily should be considered the preferred regimen for S-ASCVD patients with low bleeding risk.

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: May 1, 2023

References

  • 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
    Visseren, FLJ; Mach, F; Smulders, YM; Carballo, D; Koskinas, KC; Bäck, M
  • Randomized trial of ticagrelor vs aspirin in patients after coronary artery bypass grafting: the TiCAB trial
    Schunkert, H; Boening, A; von Scheidt, M; Lanig, C; Gusmini, F; de-Waha, A
  • Rivaroxaban: A review for secondary CV prevention in CAD and PAD
    Scott, LJ
  • International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
    Bhatt, DL; Steg, PG; Ohman, EM; Hirsch, AT; Ikeda, Y; Mas, JL
  • Burden of coronary artery disease and peripheral artery disease: A literature review
    Bauersachs, R; Zeymer, U; Briere, JB; Marre, C; Bowrin, K; Huelsebeck, M
  • A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
    Committee, CS
  • Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Bhatt, DL; Flather, MD; Hacke, W; Berger, PB; Black, HR; Boden, WE
  • Long-term use of ticagrelor in patients with prior myocardial infarction
    Bonaca, MP; Braunwald, E; Sabatine, MS
  • Ticagrelor in patients with stable coronary disease and diabetes
    Steg, PG; Bhatt, DL; Simon, T; Fox, K; Mehta, SR; Harrington, RA
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
    Eikelboom, JW; Connolly, SJ; Bosch, J; Dagenais, GR; Hart, RG; Shestakovska, O
  • 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
    Knuuti, J; Wijns, W; Saraste, A; Capodanno, D; Barbato, E; Funck-Brentano, C
  • Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis
    Mo, F; Li, J; Yan, Y; Wu, W; Lai, S
  • Antithrombotic therapy in patients receiving saphenous vein coronary artery bypass grafts: a protocol for a systematic review and network meta-analysis
    Solo, K; Martin, J; Lavi, S; Kabali, C; John-Baptiste, A; Nevis, IF
  • Efficacy and safety of long-term antithrombotic strategies in patients with chronic coronary syndrome: a network meta-analysis of randomized controlled trials
    Zhu, H; Xu, X; Fang, X; Ying, F; Song, L; Gao, B
  • Low dose rivaroxaban for atherosclerotic cardiovascular diseases: a systematic review and meta-analysis
    Chen, C; Kan, Y; Shi, Z; Guo, D; Fu, W; Li, Y
  • Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge
    Chesebro, JH; Knatterud, G; Roberts, R; Borer, J; Cohen, LS; Dalen, J
  • GRADE guidelines: 3. Rating the quality of evidence
    Balshem, H; Helfand, M; Schünemann, HJ; Oxman, AD; Kunz, R; Brozek, J
  • GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
    Guyatt, G; Oxman, AD; Akl, EA; Kunz, R; Vist, G; Brozek, J
  • Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial
    Lee, CW; Ahn, JM; Park, DW; Kang, SJ; Lee, SW; Kim, YH
  • Ticagrelor versus clopidogrel in symptomatic peripheral artery disease
    Hiatt, WR; Fowkes, FG; Heizer, G; Berger, JS; Baumgartner, I; Held, P
  • Ticagrelor with or without aspirin in high-risk patients after PCI
    Mehran, R; Baber, U; Sharma, SK; Cohen, DJ; Angiolillo, DJ; Briguori, C
  • Rivaroxaban in peripheral artery disease after revascularization
    Bonaca, MP; Bauersachs, RM; Anand, SS; Debus, ES; Nehler, MR; Patel, MR
  • Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial
    Helft, G; Steg, PG; Le Feuvre, C; Georges, JL; Carrie, D; Dreyfus, X
  • Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial
    Koo, BK; Kang, J; Park, KW; Rhee, TM; Yang, HM; Won, KB
  • Clopidogrel use as single antiplatelet therapy in outpatients with stable coronary artery disease: prevalence, correlates and association with prognosis (from the CORONOR Study)
    Lemesle, G; Schurtz, G; Meurice, T; Tricot, O; Lemaire, N; Caudmont, S
  • Duration of dual antiplatelet therapy after implantation of drug-eluting stents
    Park, SJ; Park, DW; Kim, YH; Kang, SJ; Lee, SW; Lee, CW
  • JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease
    Nakano, S; Kohsaka, S; Chikamori, T; Fukushima, K; Kobayashi, Y; Kozuma, K
  • JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease
    Nakamura, M; Kimura, K; Kimura, T; Ishihara, M; Otsuka, F; Kozuma, K
  • Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials
    Udell, JA; Bonaca, MP; Collet, JP; Lincoff, AM; Kereiakes, DJ; Costa, F
  • Direct anticoagulants and risk of myocardial infarction, a multiple treatment network meta-analysis
    Kupo, P; Szakacs, Z; Solymar, M; Habon, T; Czopf, L; Hategan, L
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
    Anand, SS; Bosch, J; Eikelboom, JW; Connolly, SJ; Diaz, R; Widimsky, P
  • Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding
    Mant, J
  • Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding
    Ray, WA; Chung, CP; Murray, KT; Smalley, WE; Daugherty, JR; Dupont, WD
  • Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, Placebo-Controlled trial
    Moayyedi, P; Eikelboom, JW; Bosch, J; Connolly, SJ; Dyal, L; Shestakovska, O
  • Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin
    Moayyedi, P; Eikelboom, JW; Bosch, J; Connolly, SJ; Dyal, L; Shestakovska, O
  • 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC
    Hindricks, G; Potpara, T; Dagres, N; Arbelo, E; Bax, JJ; Blomström-Lundqvist, C
  • Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective
    Ademi, Z; Zomer, E; Tonkin, A; Liew, D
  • Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: an Australian healthcare perspective
    Zomer, E; Si, S; Hird, TR; Liew, D; Owen, AJ; Tonkin, A